# ETX-929

Source: https://onco.cc/drugs/etx-929/  
OnCo record `etx-929` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ETX-929 is an experimental small molecule from Ensem Therapeutics, in phase 1 trials for metastatic colorectal cancer, pancreatic ductal adenocarcinoma and non-squamous non-small cell lung cancer and other cancers.

## Summary

ETX-929 is a small molecule (oral capsule) from Ensem Therapeutics. An oral pan-KRAS inhibitor that spares HRAS and NRAS and inhibits both the GTP (on) and GDP (off) states, for KRAS-mutant (G12X/G13X/Q61H) and wild-type amplified tumours. Its furthest stage is phase 1, for metastatic colorectal cancer, pancreatic ductal adenocarcinoma, non-squamous non-small cell lung cancer and endometrial adenocarcinoma. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT07912593 (Ensem sponsor), recruiting, actual start 22 Oct 2026, alone and with cetuximab. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: ETX-929
- Modality: Small molecule (oral capsule)
- Mechanism: An oral pan-KRAS inhibitor that spares HRAS and NRAS and inhibits both the GTP (on) and GDP (off) states, for KRAS-mutant (G12X/G13X/Q61H) and wild-type amplified tumours.

## Sources

- Ensem Therapeutics: ensemtx.com: https://ensemtx.com/science/pipeline/
- Ensem Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07912593
- ClinicalTrials.gov: trials of ETX-929: https://clinicaltrials.gov/search?intr=ETX-929

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- companies: [Ensem Therapeutics](https://onco.cc/companies/ensem-therapeutics/)
- trials: [Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct07912593/)

---
JSON: https://onco.cc/api/v1/entities/etx-929.json